Gala presents women-focused care, AltRx displays promotional compounded rates and a broader medicine menu, and Trimi explains different monthly and prepaid terms. The first step is identifying the precise offer.

Use the public offer details below to prepare questions. A licensed clinician should decide which treatment is appropriate; a listing order or sale price is not a clinical comparison.

Make the prices comparable

Trimi’s lowest semaglutide and tirzepatide monthly equivalents are tied to annual up-front commitments. AltRx’s current page has several promotional rate references. Request Gala’s complete quote, then compare the actual charge and term for each plan.

What each provider publicly describes

Gala Health: Ask for an itemized quote naming the medication, whether it is compounded or branded, the amount supplied, and the renewal amount. Confirm whether consultation, shipping, and continuing support are included.

AltRx: The live homepage advertised compounded GLP-1 from $89 and GLP-1/GIP from $149 during research, while another cost table used a different figure for the second option. Treat these as promotional information and request the price and term in writing.

Trimi: Trimi’s detailed page lists semaglutide at $99 per month on a twelve-month plan billed $1,188 up front, or $175 month to month. Tirzepatide is listed at $125 per month on an annual plan billed $1,500 up front, or $235 month to month. Confirm current plan terms and checkout amounts.

Questions before choosing

Ask each service for the actual ingredients, route, amount supplied, dispensing pharmacy, first payment, ongoing payment, and commitment. Keep branded and compounded products distinct.

Confirm the clinical practice, how to contact the prescriber, refill assessment, and cancellation deadline. Marketing about results or convenience does not establish which provider is clinically superior.

Continue your comparison

Compare the GLP-1 programs, read the CoreAge Rx review, and use the program table to prepare questions about the complete offer.

Provider details: Gala Health · AltRx · Trimi

Sources & offer details

Public information retrieved on October 1, 2026. Provider statements describe the advertised offer; they do not independently establish treatment outcomes.

  1. Gala Health: Official information ↗
  2. AltRx: Official information ↗
  3. Trimi: Official information ↗
  4. FDA: Unapproved GLP-1 drug concerns ↗